Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3844 - Estimated Costs of Treatment-Related Adverse Events (TRAEs) for Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the CheckMate 141 Trial

Date

10 Sep 2017

Session

Poster display session

Presenters

Meena Venkatachalam

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

M. Venkatachalam1, S. Bobiak2, J.W. Shaw2, I. Santi3, M. Contente2, B. Korytowsky2, D.D. Stenehjem4

Author affiliations

  • 1 Oncology, PAREXEL International, 02451 - Waltham/US
  • 2 Oncology (heor), Bristol-Myers Squibb, Princeton/US
  • 3 Oncology, PAREXEL International, Waltham/US
  • 4 Pharmacy Practice And Pharmaceutical Sciences, University of Minnesota, Duluth/US
More

Resources

Abstract 3844

Background

Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, is approved in the United States and the European Union for treatment of SCCHN progressing on or after platinum-based chemotherapy. In the phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival vs investigator’s choice (IC) of standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab) in patients with R/M SCCHN. This study assessed the estimated costs of managing grade 3–4 TRAEs requiring treatment in CheckMate 141.

Methods

The frequency, grade, and attribution of TRAEs for which treatment was received were extracted from CheckMate 141 patient-level safety data. Grade 3–4 TRAE treatment costs were estimated based on principle diagnosis codes of the International Classification of Disease, 9th Revision in the Healthcare Cost and Utilization Project National Inpatient Sample data (2012–2014), adjusted to reflect 2013-equivalent US costs.

Results

Among the 347 patients in the safety population, 236 received nivolumab and 111 received IC. A total of 88 grade 3–4 TRAEs requiring treatment were observed: 28 among patients receiving nivolumab and 60 among patients receiving IC. The cost of managing TRAEs per treated patient was 4.5 times higher in the IC arm ($4913) than in the nivolumab arm ($1072). Patients receiving docetaxel and methotrexate had the highest incidence of TRAEs and estimated TRAE management costs (Table).Table:

1056P

Nivolumab (n = 236)IC (combined) (n = 111)IC
Cetuximab (n = 13)Docetaxel (n = 52)Methotrexate (n = 46)
Number of grade 3–4 TRAEs requiring treatment (%)28/88 (31.8)60/88 (68.2)2/60 (3.3)36/60 (60.0)22/60 (36.7)
Total estimated cost of managing grade 3–4 TRAEs, $253,067545,37417,855333,307194,211
Cost of managing grade 3–4 TRAEs, mean per treated patient, $10724913137364104222

Conclusions

Patients with platinum-refractory R/M SCCHN treated with nivolumab had fewer grade 3–4 TRAEs, lower estimated total costs of managing TRAEs, and reduced TRAE costs per treated patient compared with standard, single-agent systemic therapy.

Clinical trial identification

NCT02105636

Legal entity responsible for the study

Bristol-Myers Squibb

Funding

Bristol-Myers Squibb

Disclosure

S. Bobiak: Former Bristol-Myers Squibb employee (at the time the submitted work was started); Spouse is current employee of Bristol-Myers Squibb. J.W. Shaw, M. Contente, B. Korytowsky: Bristol-Myers Squibb employee and shareholder. D.D. Stenehjem: Consulting fees from Bristol-Myers Squibb; Unrestricted research grant (unrelated to work regarding the content of this abstract) from Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.